Companies capable of hypergrowth often see their stock prices bid up to outrageous levels. Often, however, shares remain a ...

There will be others, especially as its bottom line and free cash flow are impressive. The company's net income grew by 54.5% ...

While it will be at least a few years before those more powerful gene editing therapies get approved for sale, assuming they ever are ... that possibility is another solid reason to buy the stock ...